Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Dabigatran Etexilate Krka 150 mg hard capsules

Active Ingredient:
dabigatran etexilate
Company:  
Krka UK Ltd See contact details
ATC code: 
B01AE07
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Dabigatran Etexilate Krka Patient Alert card

{healthcare_pro_orange} For Healthcare Professionals

Patient alert card

{pdf_link}

Dabigatran Krka Prescriber Guide for paediatrics

{healthcare_pro_orange} For Healthcare Professionals

Dabigatran Krka Prescriber Guide for paediatrics

{pdf_link}

Dabigatran Krka Prescriber Guide SPAF DVT PE

{healthcare_pro_orange} For Healthcare Professionals

Dabigatran Krka Prescriber Guide for;

• Stroke prevention in atrial fibrillation

• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (DVT/PE)

{pdf_link}

Dabigatran Krka Prescriber Guide VTE

{healthcare_pro_orange} For Healthcare Professionals

Dabigatran Krka Prescriber Guide for primary prevention of venous thromboembolic events (VTE) following elective total hip or knee replacement surgery

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Krka UK Ltd
Company image
Address
KRKA UK Ltd, Thames House, Waterside Drive, Langley, Slough, SL3 6EZ, UK
Telephone
+44 (0)207 164 6156
Medical Information Direct Line
+44 (0)7572 410 233
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)7894 980 624
Stock Availability
[email protected]
WWW
www.krka.co.uk